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Abstract
Background: X-linked hypophosphatemia (XLH) is an inherited disease of phosphate metabolism in which inactivating
mutations of the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene lead to local and systemic effects
including impaired growth, rickets, osteomalacia, bone abnormalities, bone pain, spontaneous dental abscesses, hearing
difficulties, enthesopathy, osteoarthritis, and muscular dysfunction. Patients with XLH present with elevated levels of
fibroblast growth factor 23 (FGF23), which is thought to mediate many of the aforementioned manifestations of the
disease. Elevated FGF23 has also been observed in many other diseases of hypophosphatemia, and a range of animal
models have been developed to study these diseases, yet the role of FGF23 in the pathophysiology of XLH is
incompletely understood.
Methods: The role of FGF23 in the pathophysiology of XLH is here reviewed by describing what is known about
phenotypes associated with various PHEX mutations, animal models of XLH, and non-nutritional diseases of
hypophosphatemia, and by presenting molecular pathways that have been proposed to contribute to
manifestations of XLH.
Results: The pathophysiology of XLH is complex, involving a range of molecular pathways that variously contribute to
different manifestations of the disease. Hypophosphatemia due to elevated FGF23 is the most obvious contributor,
however localised fluctuations in tissue non-specific alkaline phosphatase (TNAP), pyrophosphate, calcitriol and direct
effects of FGF23 have been observed to be associated with certain manifestations.
Conclusions: By describing what is known about these pathways, this review highlights key areas for future research
that would contribute to the understanding and clinical treatment of non-nutritional diseases of hypophosphatemia,
particularly XLH.
Keywords: X-linked hypophosphatemia (XLH), fibroblast growth factor 23 (FGF23), phosphate regulating endopeptidase
homolog, X-linked (PHEX), hypophosphatemia, vitamin D deficiency, rickets, osteomalacia, bone dysplasia, ectopic
calcification, muscle weakness, dental abscess, hearing impairment
Background and Introduction
X-linked hypophosphatemia (also known as X-linked
hypophosphatemic rickets, XLH; OMIM: #307800) is
an inherited disease of phosphate metabolism, where
inactivating mutations of the Phosphate Regulating
Endopeptidase Homolog, X-Linked (PHEX, OMIM:
#300550) gene lead to local and systemic effects. XLH
affects approximately 1:20,000 individuals [1] who ex-
perience a diverse range of medical problems that are
depicted in Fig. 1, and include impaired growth, rickets,
osteomalacia, bone abnormalities, bone pain, spontan-
eous dental abscesses, hearing difficulties, enthesopa-
thy, osteoarthritis, and muscular dysfunction [2, 3].
PHEX is predominantly expressed in osteoblasts and
codes for an enzyme that degrades local small
integrin-binding ligand, N-linked glycoproteins (SIBLING
proteins), particularly osteopontin (OPN) [4], and sup-
presses serum levels of the phosphatonin, fibroblast growth
factor 23 (FGF23). Despite being an enzyme, PHEX is
thought to affect expression [5] rather than degradation of
FGF23 [6, 7].
* Correspondence: ravi@medialis.co.uk
9Medialis Ltd, Banbury, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Beck-Nielsen et al. Orphanet Journal of Rare Diseases           (2019) 14:58 
https://doi.org/10.1186/s13023-019-1014-8
Downregulation of PHEX in XLH increases skeletal
OPN deposition which contributes to local inhibition of
mineralisation [4]. Meanwhile, elevated levels of serum
FGF23 increase urinary phosphate excretion by down-
regulating renal sodium-phosphate transporters, and
limit intestinal phosphate absorption by restricting active
vitamin D synthesis to levels that are abnormally low or
normal despite hypophosphatemia [8] .
Since phosphate insufficiency and inappropriately
low levels of calcitriol [also known as 1,25(OH)2D or
active vitamin D] contribute to many symptoms of
XLH, conventional therapy involves supplementation
with oral phosphate and calcitriol or calcitriol ana-
logues (commonly alfacalcidol). This can correct lower
limb deformities, promote growth, and improve oral
health [9], with earlier treatment leading to better
results [10]. However, conventional therapy insuffi-
ciently corrects the biochemistry and symptoms of
XLH, and can further increase serum FGF23 levels
[8, 11–13]. Conventional therapy has also been asso-
ciated with adverse effects including secondary
hyperparathyroidism, nephrocalcinosis, nephrolithia-
sis, and cardiovascular abnormalities [14].
Although hypophosphatemia is the primary link be-
tween elevated FGF23 and the pathophysiology of XLH,
FGF23 has recently been proposed to also contribute to
XLH via other molecular mechanisms [7, 15].
This review describes the central role of FGF23 in
XLH pathophysiology, outlining evidence that links
upregulation of FGF23 to manifestations of XLH
through various molecular pathways (outlined in Fig. 2).
FGF23 is introduced along with its direct regulators and
receptors, followed by a brief discussion of the dysregu-
lation of serum FGF23 in various diseases of hypopho-
sphatemia; animal models of these diseases are also
described since they are essential for understanding mo-
lecular mechanisms involved in the pathology of XLH.
Finally, the manifestations of XLH are grouped by mo-
lecular mechanism and discussed, with any potential in-
volvement of FGF23 highlighted.
Regulation of serum FGF23
The FGF23 gene is located on chromosome 12 and codes
for a 251-amino acid, 32 kDa pro-protein. Although
FGF23 is predominantly expressed in and secreted by os-
teocytes and osteoblasts, lower levels of FGF23 expression
Fig. 1 Symptomatology and pathophysiology of XLH. The signs, symptoms, sequelae, and long-term consequences of XLH in paediatric (left) and
adult (right) patients
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have been detected in rodents in many non-bone tissues,
including teeth and brain [16–18].
A 24-amino acid signalling peptide is cleaved from
FGF23 post-translationally and directs active FGF23
protein (227 amino acids) to the Golgi apparatus for
secretion. Some active FGF23 is further cleaved during
secretion, and the resulting C- and N-terminal frag-
ments are then released from the cell along with the
remaining active FGF23; these FGF23 fragments are
not thought to have any innate biological activity [19,
20] . FGF23 can either act locally or enter the blood-
stream to interact with distant cell surface receptors.
Fig. 2 Regulation of FGF23 expression and secretion in XLH. Inactivating mutations in PHEX increase fibroblast growth factor 23 (FGF23)
expression by increasing levels of acidic serine aspartate-rich-MEPE-associated protein (ASARM) peptide. This leads to increased release of FGF23
into the serum, and increased levels of FGF23-mediated signalling. These processes are also regulated by a wide range of other mechanisms.
Green lines indicate upregulation and red lines indicate repression. For simplification, feedback loops have been represented as linear pathways
centred around FGF23
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The molecular pathways involved in regulation of these
processes are complex, and therefore are only briefly
depicted in Fig. 2 and summarised below.
Factors that regulate FGF23 expression
Expression of FGF23 is predominantly regulated by
serum phosphate and calcitriol [21]. Phosphate-induced
elevation of serum FGF23 mostly occurs in bone [22].
The nature of this “phosphate sensing” mechanism is yet
to be fully elucidated, but has been proposed to involve
nicotinamide adenine dinucleotide phosphate (NAD-
PH)-induced production of reactive oxygen species
(ROS), and the mitogen-activated protein kinase
kinase-extracellular signal-regulated kinases (MEK-
ERK) pathway [23, 24]. Other molecular mechanisms
that have been associated with FGF23 expression in-
clude FAM20C [25], ENPP1 [26] and DMP1 [27], as
well as the presence of SIBLING protein-derived
acidic serine aspartate-rich-MEPE-associated protein
(ASARM) peptides [28].
Recent additions to the long list of factors proposed to
affect FGF23 expression include actin cytoskeleton reorga-
nisation, NFκB signalling [29], aldosterone [30], ORAI1
[31], changes in calcium concentrations, activated renin
angiotensin system, KLOTHO [32], and local osteoblastic
conversion of 25(OH)D to calcitriol [33].
Factors that regulate FGF23 cleavage
Degradation of FGF23 has been proposed to be medi-
ated by furin [19] and/or proprotein convertase, subtili-
sin/kexin-type 5/6 (PC5/6) [34], and to be inhibited by
O-glycosylation at the site of proteolysis by polypeptide
N-acteylgalatosaminyltransferase 3 (GalNAcT3), which
is encoded by the GALNT3 gene [35, 36]. Homozygous
inactivating mutations in GALNT3 result in low levels of
intact FGF23 and familial tumoral calcinosis syndrome,
a condition characterised by hyperphosphatemia and
extraskeletal calcifications [37]. There is also evidence
that O-glycosylation can be blocked by FAM20C-medi-
ated phosphorylation [19], and that FGF23 can be
cleaved by proprotein convertases [38], although these
findings have been challenged [34].
A recent study found that both expression and cleav-
age of FGF23 was promoted by iron deficiency and
inflammation, so that secretion of C-terminal fragments
was upregulated without significantly affecting serum
concentrations of active FGF23 [39].
While it is important to appreciate the complexity of
FGF23 regulation and to recognise that PHEX mutations
disrupt a finely balanced system, many of the aforemen-
tioned pathways have already been well-reviewed [40,
41] and a more detailed description of them is beyond
the scope of the current article.
FGF23 receptors and signalling
The poor in vitro affinity of FGF23 for its receptors made it
seem like an unlikely candidate for the then putative phos-
phatonin [42]. However, poor receptor-ligand affinity is
overcome in vivo via utilisation of co-receptors, particularly
α-KLOTHO (KLOTHO), which is schematically repre-
sented in Fig.3. Receptors for FGF23 include FGF receptor
(FGFR)1, FGFR2, FGFR3, and FGFR4, and the expression
of these receptors varies between cell types [43, 44]. In
addition, FGF23 has unusually poor affinity for heparan
sulfate (HS) that allows it to diffuse through the HS-rich
Fig. 3 FGF23-receptor interactions. Schematic diagram of known and potential interactions between FGF23 (green circle) and its various
receptors (blue and yellow). (left) FGF23 is known to bind in a KLOTHO (red)-dependent fashion to FGFRs 1, 2, and 3, (centre) and to bind to
FGFR4 independently of KLOTHO. (right) KLOTHO-independent interactions with other receptors have also been proposed
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extracellular matrix more readily than other FGFs, and to
signal in an endocrine fashion [45].
KLOTHO greatly enhances the affinity of FGF23 for
FGFR1 and FGFR3 [43] and is required for many func-
tions of FGF23. The close relationship between
KLOTHO and FGF23 is highlighted in KLOTHO-defi-
cient (Klotho-/-) mice, which display a very similar
phenotype to Fgf23-/- mice, even when they are forced to
overexpress FGF23 [43, 46, 47]. In addition, it was demon-
strated that the shed extracellular domain of α-KLOTHO
(α-KlOTHOecto) serves as a non-enzymatic molecular
scaffold for FGF23 hormone signalling. α-KlOTHOecto is
able to form a 1:1:1 ternary complex together with FGF23
and FGFR1 by implementing FGF23-FGFR1 proximity
and conferring stability. As demonstrated for membrane
bound α-KLOTHO, this is followed by heparan sulfate
facilitated dimerisation of two ternary complexes promot-
ing FGF23 signalling (Fig. 3).
KLOTHO expression was originally thought to limit
FGF23 activity and to be restricted to the kidney, parathy-
roid gland and choroid plexus [48]. However, recent reports
of widespread KLOTHO expression [48], α-KlOTHOecto
mediated FGFR activation, and KLOTHO-independent
functions of FGF23 [49] have expanded the proposed scope
of FGF23 activity.
Post-cleavage C-terminal fragments of FGF23 have also
been shown to block formation of FGF23-FGFR-KLOTHO
complexes and to improve hypophosphatemia, which adds
another regulatory level to FGF23 signalling [50].
Serum FGF23 and non-nutritional diseases of
hypophosphatemia
Serum FGF23 is elevated in many non-nutritional dis-
eases of hypophosphatemia, and the main characteristics
that lead to differential diagnosis of these diseases are
outlined in Table 1.
FGF23 was originally identified for its role in phos-
phate metabolism when mutated FGF23 was found in
patients with autosomal dominant hypophosphatemic
rickets (ADHR) [51], and FGF23 was identified as the
causal agent in tumour-induced osteomalacia (TIO).
Indeed, most inherited forms of hypophosphatemia are
caused by mutations that directly increase serum con-
centrations of FGF23 and/or the activity of its receptors.
The three forms of autosomal recessive hypophosphatemic
rickets (ARHR) result from mutations in DMP1 [ARHR1,
[52]], ENPP1 [ARHR2, [26]], and FAM20C [ARHR3, [25]],
while hypophosphatemic rickets and hyperparathyroidism
(HRHPT) is caused by mutations that upregulate KLOTHO
expression [53].
A key exception to the rule is hereditary hypophosphate-
mic rickets with hypercalciuria (HHRH) in which patients
show suppressed or low-normal FGF23 levels. HHRH is
caused by mutations in the renal phosphate transporter
NPT2C [also known as NaPi-IIc or solute carrier family 34
member 3 (SLC34A3)]. Phosphate-independent effects of
FGF23 can therefore be identified by comparing the patho-
physiology of patients with HHRH to those with
FGF23-high hypophosphatemias [54] (Table 1).
TIO is an interesting example of an FGF23-mediated
hypophosphatemia, as this acquired disease is caused by
FGF23-secreting tumours, whose total resection is com-
pletely curative [55]. Symptoms of TIO can therefore be
unambiguously attributed to over-expression of FGF23
and/or other tumour-secreted phosphatonins, without po-
tential confounding contributions to the clinical phenotype
from mutated genes.
Finally, XLH is the most common form of non-nutritional
hypophosphatemia. The mechanisms by which PHEX
mutations lead to elevated FGF23 levels remain poorly
understood and have been attributed to increased expression
[5] and reduced degradation [38, 40] of FGF23.
PHEX mutations and FGF23 regulation in XLH
Around 350 different PHEX mutations have been identified
to date, including nonsense, missense, frameshift, splice site,
deletion, and duplication mutations [56] – the mutations
are represented in Fig. 4. Mutations have been observed to
affect each of the 22 PHEX exons, as well as intronic splice
sites [57–59] and the 5’ untranslated region [57].
Identifying consistent genotype-phenotype relation-
ships in patients with mutations affecting similar genetic
loci would indicate connections between those PHEX
loci and specific phenotypes. The presence or absence of
a correlation between such mutations and serum levels
of FGF23 could further elucidate the role of PHEX in
regulating FGF23, and/or the roles of PHEX and FGF23
in the pathophysiology of XLH. Indeed, specific muta-
tions have been associated with specific manifestations
of XLH [56], and attempts have been made to connect
serum levels of FGF23 to severity of XLH [8].
PHEX mutations can lead to retention of PHEX
protein in the endoplasmic reticulum [60] and/or
expression of truncated PHEX proteins which may
retain some functions of the full-length protein [61, 62].
Identifying direct functions of PHEX that may be
retained in truncated proteins would therefore contrib-
ute to our understanding of the aetiology of XLH.
One mechanism by which the full-length PHEX pro-
tein has been proposed to regulate serum FGF23 is in-
direct cleavage by proprotein convertases [6, 40]. The
proprotein convertase, subtilisin/kexin-type 2 (PC2) has
been reported to be upregulated by PHEX, to cleave
FGF23 directly [40], and to promote formation of
PHEX-DMP1-integrin complexes that suppress FGF23
when activated by neuroendocrine protein 7B2 (7B2•PC2)
[38]. However, the potential for a direct interaction be-
tween 7B2•PC2 and FGF23 may be confounded by an
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apparent lack of potential for physical contact between the
two proteins [34]. Interactions between 7B2•PC2 and the
FGF23-regulator FAM20C may [63] or may not [34] also
affect interpretation of these studies.
However, studies searching for genotype-phenotype
correlations in XLH patients have so far failed to identify
significant correlations [64–67]. Reaching statistical sig-
nificance in these studies is complicated by the rarity of
the disease, the sheer diversity of mutations in XLH
patients and the impact of conventional treatment on
the natural course of the disease [65].
Although mutations can be grouped by locus [64] or by
mutation type [66], larger data sets are ultimately required
to establish specific genotype-phenotype correlations. The
observation that disease severity may vary considerably in af-
fected members of the same family indicates that there are
other modifying factors and that a clear genotype-phenotype
correlation may be difficult to identify [68].
Animal models of XLH
Despite the lack of obvious genotype-phenotype correl-
ation in individuals with PHEX mutations, phenotypic
differences have been observed between various animal
models of XLH, which are easier to study but are not
precisely representative of the patient population.
Mouse models possessing at least six different muta-
tions of the Phex gene (Gy, Hyp, Hyp-Duk, Hyp-2J, Ska1
and Jrt) have been used to study XLH and are described
in Table 2. The phenotypes of these mice vary depending
on the specific Phex mutation and the mouse strain.
Although these differences are rarely discussed in pub-
lished works, they can shed light on FGF23-independent
roles of PHEX in XLH pathology and resolve apparent
contradictions in the literature.
Phex-non-specific animal models of XLH
The first two mouse models of XLH were named Hyp
and Gy [69, 70]. Although both mice displayed hypopho-
sphatemia and broadly similar phenotypes, Gy mice
additionally displayed inner ear abnormalities and male
sterility. The two models were originally thought to
possess mutations in related X-linked genes, but Gy and
Hyp have since been identified as mutations that both
ablate the Phex gene (Table 2). While Hyp mice have
mutations that affect exon 15 and 10 kb of downstream
intergenic sequences, Gy mice contain large deletions of
Fig. 4 Mutation analysis of human PHEX. Mutations that span multiple exons (top section) are represented by lines, while intron-specific (middle section)
and exon-specific (lower section) mutations are clustered by loci. Affected nucleotides are numbered. A, adenine; C, cytosine; G, guanine; T, thymine; del,
deletion mutations; dup, duplication mutations; ins, insertion mutations; delins, combination deletion/insertion mutations; >, substitution mutations [56]
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Phex exons 1-3 [71, 72]. The Gy deletion also extends
upstream into the neighbouring spermine synthase
(SmS) gene, which has been associated with hearing loss
and infertility, thus confounding Gy mice as a model of
XLH-related hearing loss [73].
Forced expression of human transgenic FGF23 has
been shown to rescue the bone phenotype of Hyp mice,
but not their hypophosphatemia [74]. This result may be
due to phosphate-independent effects of FGF23 on bone,
or the Hyp mutation affecting expression of other genes
or signal peptides involved in phosphate regulation and/
or bone mineralisation.
Phex-specific models of XLH include Ska1 mice, which
contain a chemically-induced point mutation in a splice
donor site just after exon 8 [75], PhexK496X (Jrt) mice,
which contain a stop codon at amino acid 496 [76], and
Hyp-2J and Hyp-Duk mice [77], which contain larger
frameshift deletions. Phenotypic differences between
Hyp-2J and Hyp-Duk mice have been observed and are
discussed below. The Hyp-Duk mutation can result in
the production of truncated PHEX proteins, which may
retain some functions of PHEX [62].
Despite the range of animal models available, major
challenges remain for elucidating the pathogenesis of
XLH including: the low disease prevalence, the complex-
ity of FGF23-related molecular networks, the diversity of
PHEX mutations, the potential for residual PHEX func-
tion, and the potential impact of random X-inactivation
on the severity of the female phenotype. Considering
these challenges, known and proposed role(s) of FGF23
in XLH sequelae are discussed below.
The role of FGF23 in XLH pathogenesis
When FGF23 was first described as the causative agent
of ADHR, the authors commented on the similarities be-
tween ADHR and other diseases of inherited hypopho-
sphatemia, including XLH [51]. The relationship
between FGF23 and the pathophysiology of diseases of
inherited hypophosphatemia has since been well-studied
by comparing phenotypes of patients with FGF23-high
and FGF23-normal hypophosphatemias (Table 1) to
animal models (Table 2), healthy controls, and cases
where FGF23 levels have been lowered, including block-
ing and knock-out experiments.
Multiple pathways link elevated FGF23 to long bone
abnormalities
Abnormal, disproportionate growth is a definitive feature
of XLH and is primarily seen in reduced growth of
endochondral long bones. Within the first few months
of life, signs and symptoms of the disease become evi-
dent. Uncontrolled rickets and osteomalacia contribute
to continuously diminished leg growth, which leads to
short stature with elevated sitting height index (i.e. ratio
between sitting height and stature), gait abnormalities
due to deformities and muscle weakness, bone pain, de-
formity of weight-bearing limbs, with the development
of Looser zones becoming evident in the mature skel-
eton (Fig. 1) [9, 78].
Briefly, endochondral bones develop from cartilagin-
ous precursors that mineralise outwards from ossifica-
tion sites. The cartilage remaining between ossification
sites continues to grow, forming epiphyseal growth
plates composed of germinal, proliferative and (upper
and lower) hypertrophic zones. After completing active
mitosis in the proliferative zone, epiphyseal chondro-
cytes of the upper hypertrophic zone enlarge and form
columns that lengthen the developing bone, while chon-
drocytes of the lower hypertrophic zone mineralise the
surrounding matrix and produce vascular endothelial
growth factor that attracts invading vessel and bone cells
[79]. The terminal hypertrophic chondrocytes undergo
apoptosis and are replaced by osteocytes and osteoid
that is then overlaid with hydroxyapatite to form miner-
alised bone [80, 81].
In hypophosphatemia, apoptosis of hypertrophic chon-
drocytes is arrested and is, by an unknown mechanism,
followed by decreased chondrocyte proliferation and loss
of organisation of the proliferative columns [80]. In
addition, hypomineralisation of the newly formed bone
leads to accumulation of osteoid and weakened bones.
When pressure is applied to affected bones they bend



















Gy Deletion (160-190 kb) UTR+1-3 N ↑ ↓ Y N Y [73]
Hyp Deletion (58 kb) 15-22+UTR N ↑ ↓ Y Y N [71]
Hyp-Duk Deletion (30 kb) 13-14 Y ↑ ↓ Y Y Y [62]
Hyp-2J Deletion (7.3 kb) 15 Y ↑ ↓ Y Y N [62]
Ska1 Point mutation (1 bp) 8 Y ↑ ↓ Y ? ? [75]
Jrt Point mutation (1 bp) 14 Y ↑ ↓ Y ? ? [76]
The size and type of mutations, the exons affected and whether or not the mutations are restricted to the Phex coding region are presented alongside the
phenotypic profile of the mice. Y, yes/present; N, no/absent; ?, not reported; UTR, untranslated region
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under pressure, while loading appears to affect the func-
tion of hypomineralised growth plates, which collectively
cause leg length to be more affected than arm span in
XLH patients [57].
On the other hand, osteomalacia is caused by a gener-
alised disruption of mineral deposition of newly-formed
osteoid. Unlike rickets, which is a disease of the growth
plates and thus only affects children, osteomalacia can
affect both children and adults with XLH [81].
A role for FGF23 in the pathogenesis of rickets and
osteomalacia in TIO was identified shortly after its discov-
ery [82], and was supported by the consistent appearance
of bone abnormalities in FGF23-high diseases and animal
models (Tables 1 and 2). Furthermore, the skeletal pheno-
types of Hyp mice in which Fgf23 was also ablated
(Hyp-Fgf23-/-) were more similar to Fgf23-/- mice than to
Hyp mice [83]. The molecular pathways connecting FGF23
to abnormal bone development have since been further
elucidated and include hypophosphatemia-mediated path-
ways and autocrine/paracrine pathways, which are respect-
ively illustrated in parts A and B of Fig. 5 [84, 85].
Hypophosphatemia-mediated mechanisms of FGF23-
induced bone abnormalities
Hypophosphatemia is the primary mechanism by which el-
evated serum FGF23 affects bone development. Excess
FGF23 results in hypophosphatemia, whether induced by
direct injection [86] or increased stability [87, 88] of FGF23
(Fgf23-TG), or by downregulation of FGF23-suppressors
including PHEX [5, 25, 52].
Hypophosphatemia leads to rickets by inhibiting
mineralisation and apoptosis of hypertrophic chondro-
cytes [89], yet the contributions of FGF23 to hypo-
phosphatemia are mediated by a complex network of
pathways that ultimately increase urinary wasting, due
to downregulation of the renal sodium-phosphate
co-transporters NPT2A and NPT2C [90, 91], and
decrease intestinal absorption of phosphate (Fig. 5a)
[80, 81].
NPT2A and NPT2C play different roles in mice and
humans. While humans develop severe hypophosphate-
mia (HHRH) when NPT2C is lost, depletion of
Npt2c-alone in mice has no apparent effect on phos-
phate metabolism [54]. Depletion of Npt2a-alone
results in upregulation of Npt2c and a mild hypopho-
sphatemia and bone phenotype [54]. Yet mice missing
both Npt2a and Npt2c display severe hypophosphate-
mia and rickets, as well as hypercalciuria, indicating a
functional redundancy that is not seen in humans [92].
Such inter-species variation in gene function is a chal-
lenge for translating the study of these genes [93].
Nevertheless, the relationship between FGF23 and these
phosphate channels is clear; direct administration of re-
combinant FGF23 has been seen to reduce renal expression
of NPT2A in mice [94], and renal expression of NPT2A
and/or NPT2C is downregulated in FGF23-high mice (Hyp
or Fgf23-TG) and in patients with XLH [3, 90, 95].
Increased FGF23 affects calcitriol synthesis and degrad-
ation, thus hindering its ability to counterbalance hypopho-
sphatemia. FGF23 downregulates renal 1α-hydroxylase
(CYP27B1) and stimulates expression of 24-hydroxylase
(CYP24A1), which limits production and increases degrad-
ation of calcitriol [15]. FGF23 also suppresses the secretion
of PTH, which would otherwise promote expression of calci-
triol [96], reducing intestinal adsorption of phosphate [97].
PTH is suppressed via MAPK/ERK signalling both in
KLOTHO-dependent and -independent manners involving
activation of the calcineurin-nuclear factor of activated
T-cells (NFAT) pathway [96].
Disturbed regulation of the physiological responses of
calcitriol to hypophosphatemia, in addition to the down-
regulation of the renal phosphate transporter channels,
thus contribute to hypophosphatemia in diseases of
excess FGF23 such as XLH (Fig. 5a). FGF23-mediated
upregulation of prostaglandin E2 (PGE2) via inhibition
of proximal tubule phosphate transport may also
contribute to hypophosphatemia [98, 99], but the sup-
porting evidence is less clear, since these animal studies
were not supported by a subsequent under-powered
crossover study in children [100].
FGF23-mediated autocrine/paracrine pathways linked to
bone abnormalities
The discovery that achondroplasia (a well-known skel-
etal dysplasia in which serum phosphate is unaffected) is
caused by activating mutations of an FGF23 receptor
(FGFR3), indicated that FGF23-related pathways may
affect skeletal development in phosphate-independent
manners [101]. This prospect was supported when
abnormal mineralisation of Hyp osteocytes was observed
in a phosphate-normal in vitro environment [102].
It has since become evident that hypophosphatemia-inde-
pendent autocrine/paracrine effects of FGF23 can be medi-
ated by calcitriol and tissue non-specific alkaline
phosphatase (TNAP) (Fig. 5b).
Calcitriol-dependent pathways
A recent study linked autocrine/paracrine roles of
locally-produced calcitriol to the FGF23-mediated regu-
lation of chondrocyte differentiation and bone mineral
deposition [15].
Despite displaying hypophosphatemia and low serum
calcitriol, mice with elevated FGF23 (Hyp or Fgf23-TG)
did not develop skeletal abnormalities when CYP24A1
levels were repressed, either in Cyp24a1-null mutants or
following blocking with CTA102 [15]. It was hypothe-
sised that mineralisation in the control animals was dis-
rupted by FGF23-mediated activation of CYP24A1
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degrading locally-produced calcitriol, and CYP24A1-an-
tagonists were proposed as novel therapeutic agents for
XLH [15]. Furthermore, regulation of local CYP27B1
has recently been shown to differ between bone and kid-
ney and local regulation of calcitriol is generally poorly
understood and may be affected in XLH [103].
Conversely, there is also evidence suggesting that vita-
min D does not play a direct role in bone development.
For example, an early study in which vitamin D-deficient
rats were either given vitamin D and infused with saline,
or infused with concentrations of calcium and phos-
phorus to maintain plasma concentrations equal to those
A
B
Fig. 5 FGF23 and bone abnormalities. Schematic illustrations of (a) hypophosphatemic and (b) autocrine/paracrine molecular pathways that have
been proposed to link FGF23 to bone abnormalities in XLH
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in the vitamin D treated animals, indicated that vitamin
D did not play a role in the density or calcium-phos-
phate ratio of bone [104].
Inhibition of bone-derived calcitriol may contribute to
rickets by inhibiting chondrocyte differentiation through
downregulation of p21Waf1/Cip1 pathways and upregula-
tion of cyclin D1 [15]. Calcitriol has also been shown to dir-
ectly affect expression of OPN, a known inhibitor of
hydroxyapatite crystal formation, however studies have
indicated that calcitriol can either induce upregulation
[105] or downregulation [106] of OPN, and whilst much of
the literature suggests that calcitriol induces upregulation
of OPN, no conclusive studies are currently available.
The SIBLING protein OPN contains an ASARM
peptide motif [106, 107], cleavage of which releases
phosphorylated ASARM (pASARM) peptides which
are also potent inhibitors of mineralisation. Loose
pASARM peptides are directly and exclusively cleaved
by PHEX [4, 9, 40, 108]. Although reduced
PHEX-mediated cleavage of pASARM also acts as an
FGF23-independent mechanism for contributing to bone
abnormalities in XLH [109–112], this process is exacer-
bated by FGF23-induced upregulation of OPN [108].
Furthermore, the recent observation of impaired urinary
OPN excretion in Npt2a-/- mice could indicate another
FGF23-mediated contribution to the pASARM-mediated
demineralisation of bone [113]. However, evidence
that ablating Fgf23 can also lead to upregulation of
OPN indicates that the relationship between FGF23
and OPN is poorly understood and is likely to be
complex [114].
TNAP-dependent pathways
Recent evidence suggests that accumulation of pyro-
phosphate (PPi) may also play a role in impaired
mineralisation in XLH.
Downregulation of TNAP (expressed by Alpl) suppresses
hydrolysis of PPi and has been linked to post-natal mineral-
isation defects and hypophosphatasia, a normophosphatae-
mic disease with rickets like bone abnormalities resembling
those observed in XLH [115–117]. PPi is also a known
mineralisation inhibitor, binding to and inhibiting forma-
tion of hydroxyapatite crystals [106, 107, 118].
A study comparing mice in which Fgf23, Klotho and/or
vitamin D receptor (Vdr) genes were knocked out connected
this TNAP-dependent pathway to FGF23, as accumulation
of PPi was promoted in the osteoblastic cells of FGF23-/-
mice [49] .
The proposed autocrine/paracrine role of FGF23 was
observed to act through TNAP and PPi in Hyp mice,
whose osteoblasts and osteocyte-like cells were cultured
in vitro and ex vivo and were compared to sections of
Hyp bone [7]. Despite being separated from the in vivo
hypophosphatemic environment, TNAP was inhibited
and mineralisation defects arose in osteocyte-like cells,
where PPi deposition was promoted and hydroxyapatite-
formation was blocked [7].
That low levels of TNAP expression were observed in
osteocyte-like cells but not in osteoblasts was further
investigated and TNAP expression was found to cor-
relate inversely with FGFR3 expression levels [7].
Chondrocyte proliferation has also been suppressed
by FGFR3 activation in vivo and in vitro, resulting in
suppression of linear bone growth [119]. Activation of
FGFR3 can also lead to achondroplasia, which results
in a more extreme disproportionate short stature than
XLH. Experiments blocking FGF23 or FGFR3 demon-
strated that FGF23 was suppressing TNAP transcrip-
tion via KLOTHO-independent, FGFR3 signalling and
ultimately leading to mineralisation defects [7]. This
KLOTHO-independent pathway may explain findings
that the overexpression of FGF23 can suppress osteo-
genesis in osteoblastic cells, which do not express
KLOTHO [120].
Another key FGF23 receptor, FGFR2, also plays an im-
portant role in skeletal development [121], and was up-
regulated in the bones of Hyp mice [122]. There is a line
of evidence connecting over-expression of FGFR2 in
long bones to weakened long bones [123] via suppres-
sion of TNAP [123] and the production and accumula-
tion of PPi [124, 125] (Fig. 5b).
Interestingly, the autocrine/paracrine effects of FGF23
appear to vary between mouse models of XLH. Although
Jrt mice display growth retardation, skeletal abnormal-
ities, hypophosphatemia and increased serum FGF23
and ALP levels similar to other murine models of XLH;
unlike those models Jrt osteoblasts in vitro have been
observed to resemble those from wild type males with
respect to cellular differentiation and calcium deposition
into bone matrix [76].
The osteoblast abnormality in Jrt mice may arise from
a reduction in phosphate sensitivity mediated by Phex
independently of FGF23 [126]. While hemizygous
Phex-/Y mice (100% of cells carry one mutant Phex)
displayed comparable skeletal abnormalities to hetero-
zygous Phex-/Phex+ mice (50% of cells carry one
mutant Phex), homozygous female Phex-/Phex- mice
(100% of cells carry two mutant Phex) displayed exag-
gerated abnormalities, despite having equivalent
serum phosphate and FGF23 concentrations [127].
Skeletal abnormalities in these animals therefore
appeared to correlate with the dosage of Phex muta-
tions, which may affect random X-chromosome in-
activation or the sensitivity of osteocytes to serum
phosphate and/or FGF23.
Jrt mice are an interesting model of XLH, and should
be included in future studies investigating the roles of
PHEX and FGF23 in the disease.
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FGF23-blocking ameliorates bone abnormalities
Finally, the relevance of FGF23 to bone abnormalities in
XLH and other diseases of hypophosphatemia has been
indicated by various animal experiments and clinical tri-
als. For example, complete resection of FGF23-produ-
cing tumours has resolved hypophosphatemia,
osteomalacia, bone pain and improved other skeletal
manifestations in TIO [128, 129] and administration of
FGF23-blocking antibodies has improved growth retard-
ation of juvenile Hyp mice, accelerating weight gain,
increasing tail length, decreasing osteoid volume and
thus improving bone mineralisation while improving
elongation of femoral and tibial bones [130–132]. FGF23
antibodies have also improved levels of serum phos-
phate, serum calcitriol, and alkaline phosphatase, as well
as rickets severity (RSS), radiographic global impression
of change (RGI-C), and Western Ontario and the
McMaster Universities Osteoarthritis Index (WOMAC)
scores in clinical trials involving paediatric or adult
patients with XLH (Paediatric trial: NCT02163577;
Adult trial NCT02526160) [133–135].
Ectopic calcification and ossification in XLH
Ectopic calcification in XLH can affect the kidneys
(nephrocalcinosis), joints, and bone attachments of ten-
dons (enthesopathies) (Fig. 6). While nephrocalcinosis
has long been considered a side effect of conventional
treatment [136], enthesopathies have also been observed
in untreated patients [137].
Nephrocalcinosis
Nephrocalcinosis has been observed in as few as 22%
and as many as 100% of XLH patients [66, 138, 139].
This variation can be partially attributed to small study
sizes and high patient and treatment variability.
Nephrocalcinosis is often composed of calcium phos-
phate precipitation and is thought to be due to one or a
combination of hypercalciuria, hyperphosphaturia, hyper-
oxaluria, and secondary hyperparathyroidism [140–142].
Nephrocalcinosis has not been reported in untreated XLH
patients and is widely considered to be a result of conven-
tional therapy [143] associated with active vitamin D dos-
age [144]. In addition, other soft-tissue calcifications such
Fig. 6 FGF23 and kidney abnormalities. Elevated levels of FGF23 in XLH increase renal expression of TRPV5 calcium channels, contributing to local
excesses of calcium and general hypercalcemia, which may contribute to enthesopathies and calcification of arteries, resulting in hypertension
and cardiovascular disease. Although nephrocalcinosis occurs in XLH as a side-effect of conventional therapy, the TRPV5-mediated increase in
renal calcium absorption may play a permissive role
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as ocular, myocardial, and aortic valve calcification have
been reported in XLH patients with persistent secondary
or tertiary hyperparathyroidism and/or high dose calcitriol
and phosphate treatment [145].
The hypercalciuric properties of NPT2A/C downregu-
lation, alongside the effects of FGF23 on NPT2A/C ex-
pression, have been briefly discussed above, and the
impact of NPT2A/C impairments in patients are further
explored in the paper by Bergwitz and Jüppner [146].
Dysfunctions in NPT2A alone have been associated with
severe renal calcification [147], whilst mutations in
NPT2A and NPT2C have also been reported in patients
with renal stone disease and nephrocalcinosis [148, 149].
A recent study has also shown that upregulation of
OPN via FGF23/PHEX can contribute to nephrocalci-
nosis and nephrolithiasis observed in mice on a high-
phosphate diet [113].
A potential role for FGF23 in enhancing renal calcium
reabsorption has also been observed in XLH [150], which
may be mediated through the transient receptor potential
cation channel subfamily V member 5 (TRPV5) channel,
which promotes cellular uptake of calcium and therefore
calcification [151, 152].
Excessive mineralisation also occurs in the heart and
kidney of mice in which Fgf23 has been ablated, regard-
less of whether or not the mice possessed the Hyp muta-
tion [83]. This further illustrates the suppressive effect
FGF23 has on mineralisation.
Nephrocalcinosis has not been observed during
FGF23-blocking trials, probably because the treatment
does not include active vitamin D [130]; however,
long-term data are lacking.
Cardiovascular calcification and hypertension
Reports of cardiovascular abnormalities and hyperten-
sion in patients with XLH are rare, inconsistent, and
considered to be side effects of conventional therapy
and/or FGF23-driven increased renal sodium reabsorp-
tion [14, 66, 139, 152, 153]. Studies have reported hyper-
tension [66] and left ventricular hypertrophy in only a
minority of subjects [139], or found no evidence of
cardiovascular myocardial dysfunction symptoms in any
of 11 XLH patients [154].
A recent study of XLH patients found hypertension
correlating with reduced estimated glomerular filtration
rate (eGFR) in 6/22 patients, most of whom also had
secondary hyperparathyroidism [66]. The authors were
unable to determine whether hypertension was a pri-
mary consequence of XLH or a secondary consequence
of conventional therapy and concluded that “multiple
factors” presumably played a role [66].
The over-expression of FGF23 has also been associated
with various aspects of cardiovascular disease in chronic
kidney disease (CKD) including cardiomyocyte
hypertrophy, vascular calcification, stroke, and endothe-
lial dysfunction [155–160]. Atherosclerosis has been pro-
posed as a mechanism by which FGF23 may promote
cardiovascular events and stroke in these patients [157].
However, the pathogenic mechanism is unlikely to be
mediated by KLOTHO, which is excreted by the
CKD-affected kidney [161]. FGF23 may instead contrib-
ute to cardiovascular disease in CKD by directly inter-
acting with FGFR4 on cardiomyocytes to induce
cardiomyocyte hypertrophy [162, 163] or with hepato-
cyte FGFRs to induce hypertension [164] which can lead
to blood vessel calcification [165, 166].
In addition, FGF23 was shown to directly regulate the
membrane abundance of the Na(+):Cl(-) co-transporter
NCC in distal renal tubules by a signalling mechanism
involving the FGF receptor/αKlotho complex [152]. This
suggests that FGF23 is a key regulator of renal sodium
reabsorption and plasma volume and may explain the
association of FGF23 with cardiovascular risk in CKD
patients. In addition, FGF23 is also generally associated
with the progression of CKD [167]. Nevertheless, FGF23
levels in CKD are elevated well above those observed in
hereditary hypophosphatemia and at those concentra-
tions FGF23 may reach toxic levels that are not relevant
to XLH [168].
Enthesopathy
In patients with hereditary hypophosphatemia, inappro-
priate mineralisation of fibrocartilage can develop where
tendons insert into bone (entheses). The developing
spurs (enthesophytes) can then cause joint stiffness and
pain (enthesopathy), which often affects patients with
XLH [138]. Mineralising enthesopathies of fibrocartilagi-
nous insertion sites affect a majority of ankles in patients
with XLH, and appear to be strongly correlated with in-
creasing age [2, 169, 170]. Enthesopathies are also com-
monly observed in other phosphate-wasting disorders of
excessive FGF23 (ARHR1, AHRH2), and in murine
models of XLH (Hyp, Fgf23-TG) [171–173].
The initiation of mineralising enthesophytes at the bony
insertion site is poorly understood, but is thought to occur
following degeneration of mineralised cartilage during in-
sertion site development [174]. Expression of Fgfr3 and
Klotho in murine fibrocartilage cells indicates that they are
likely to be directly affected by FGF23 [169].
Fibrocartilage is composed of an uncalcified zone con-
taining alkaline phosphatase-negative chondrocytes, and
a calcified zone where chondrocytes express alkaline
phosphatase and are surrounded by a mineralised matrix
that covers the bone surface. Significantly greater num-
bers of alkaline phosphatase-positive fibrocartilage cells
have been observed in joints of Hyp mice than in control
mice, yet the typically narrow mineralised zone was also
completely lost [169]. The observed fibrochondrocyte
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hyperplasia was proposed to pre-date loss of the minera-
lised zone and to cause enthesopathy [169].
Enthesopathies have been observed in untreated XLH
patients [137, 175] and they have been reported to be
unaffected by conventional therapy in XLH patients
[176]. In Hyp mice conventional therapy has not only
failed to ameliorate fibrochondrocyte hyperplasia, but
also exacerbated mineralisation of enthesopathies [171].
Development of enthesopathies may be mediated by
matrix metalloproteinase 13 (MMP13), a gene that pre-
pares cartilage matrix for calcification [177] and a crit-
ical target gene during the progression of osteoarthritis.
Expression of MMP13, FGF23 and OPN are all down-
regulated in enthesopathic Hyp cartilage, but not in the
osteoblasts of those same mice. This indicates that the
downregulation of these genes is chondrocyte-specific and
may indicate that the hyperplastic chondrocytes observed
in enthesopathies are immature [174]. This observation
also highlights the importance of assessing gene expres-
sion levels of specific cell types where possible, rather than
relying on serum levels to develop mechanistic models.
Enthesopathic sites in Hyp and Fgf23-TG mice also
displayed increases in sulphated proteoglycans [171].
The cushioning effect of the sulphated proteoglycans
combined with the greater surface area of XLH bones
are thought to stabilise and protect joints from the ab-
normally high compressive forces exerted through weak-
ened and misshapen long bones [171]. Mineralising
enthesopathies may therefore be a secondary effect of
long bone hypomineralisation causing weaker and more
bendable bones, with potentially more strain on the
entheses and their attachment. Therefore, correcting
gross skeletal abnormalities and restoring normal
biomechanics may theoretically contribute to correction
of enthesopathy.
Although the effects of FGF23 blocking on enthesopa-
thies have not specifically been assessed, significant
improvements have been observed in treated XLH patients
scored on the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC), which focuses on patient
perception of joint pain [178].
Skeletal muscle defects in XLH
Muscle pain or weakness has been reported by a majority of
adult hereditary hypophosphatemic rickets patients in one
study [138], and Hyp mice display reduced grip strength and
spontaneous movement compared to controls [131].
Despite having normal muscle size, and in the absence
of leg deformities, subjects with hereditary hypopho-
sphatemic rickets had lower muscle density and lower
peak muscle force and power compared to age- and
gender-matched controls [179, 180]. Since muscle force
is strongly correlated with bone strength, and osteocytes
have been connected to muscle mass and function via
mechanical loading, PGE2 and Wnt3a [181], the abnor-
mal skeletal phenotype in XLH patients may contribute
to skeletal muscle defects.
It is also interesting to note that some studies have
found strong correlations between extremes in phos-
phate levels and impaired muscle force, whilst others
have found that hypophosphatemia appears to be associ-
ated with muscle weakness. These findings suggest that
the development of the skeletal muscle defects observed
in patients with XLH may be multifaceted [182, 183].
Skeletal muscle wasting, weakness and pain have also
been observed in patients with TIO [128, 129, 184]. The
lack of either skeletal abnormality or genetic mutation in
these patients indicates that FGF23 may contribute to
the development of these manifestations either directly
or via hypophosphatemia.
The phosphaturic actions of FGF23 may contribute to
the muscular phenotype by decreasing muscle ATP syn-
thesis and causing muscle weakness, which has been ob-
served in both HHRH patients and Npt2a-/- mice [185].
This correlation is supported by evidence that phosphate
supplementation has reversed skeletal muscle abnormal-
ities in a case of chronic fatigue [186] and reversed
muscle weakness in a patient suffering FGF23-induced
hypophosphatemic osteomalacia [187]. Phosphate sup-
plementation has also ameliorated post-operative weak-
ness and muscle tremors in a dog [188] and vitamin
D-deficiency-induced muscle weakness in rats [182].
Collectively, these results indicate that FGF23-induced
hypophosphatemia is associated with muscle weakness
in XLH. However, the expression of PHEX in myocytes
indicates the potential for a more direct role for FGF23
in muscular weakness in XLH [74], and FGF23 has been
shown to induce senescence in mesenchymal stem cells
derived from skeletal muscle [189].
On the other hand, there may be a role for
exercise-stimulated FGF23 in controlling production of
ROS production and enhancing mitochondrial function
[190]. Although FGF23 levels are likely to be consist-
ently higher in XLH than during exercise, the study by
Li et al identifies a novel effect of FGF23 on skeletal
muscle, which may be induced by the high FGF23 levels
in XLH. Plasma levels of FGF23 are also positively asso-
ciated with muscle mass in haemodialysis patients,
which could indicate a role for FGF23 in improving
muscle strength [191].
Nevertheless, resection of an FGF23-producing
tumour has resolved muscle pain in a patient with TIO
[128] and therapeutic application of an FGF23-blocking
antibody has increased grip strength and spontaneous
movement in Hyp mice [131] and led to full recovery of
bone and muscle pain when treating patients with
iron-induced FGF23-mediated hypophosphatemic osteo-
malacia [192].
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Craniosynostosis in XLH
Craniosynostosis is a cranial malformation that results
from premature fusing of the cranial sutures during de-
velopment (illustrated in Fig. 7). Beyond abnormal skull
shape, craniosynostosis and defective mineralisation in
XLH patients can be associated with Arnold-Chiari
malformations, which may cause central nervous system
problems [193] . Hypophosphatemic rickets has long
been linked to craniosynostosis [194], but the relation-
ship is poorly understood [195].
Cranial malformations arise in a range of diseases that
involve activation of FGF23 receptors, including osteo-
glophonic dysplasia (OGD) (FGFR1, [196]), Crouzon and
Apert syndromes (FGFR2, [44]) and achondroplasia
(FGFR3, [197]). Achondroplasia affects the size and
shape of the cranial base, as well as reducing length of
the nasal bone [198], which has also been observed in
patients with hereditary hypophosphatemia [199] and
Hyp mice [200].
Overexpression of FGFR2 and FGFR3 have been shown
to affect both intramembranous and endochondral ossifi-
cation in the skull [123, 197]. Beyond downregulation of
TNAP, proposed mechanisms for these changes include
TGF-β/BMP signalling (ERK1/2) and Wnt signalling [125,
201, 202], while cross-binding of FGF23 with FGFR2 and
FGFR3 at the cranial sutures has also been proposed to
contribute to craniosynostosis [203]. However, it remains
difficult to isolate these pathways as specific mechanistic
links to craniosynostosis because they have also been
linked to bone mineralisation.
Effects of blocking FGF23 on the development of
craniosynostosis have not been reported at this stage
[130, 131, 204].
Dental defects in XLH
Despite an outwardly normal dental appearance, severe
dental disease including dental abscesses, periodontal
problems and malocclusion [205] has been observed in
as many as 75% of untreated XLH patients [206].
Teeth are primarily composed of three layers, the in-
ternal pulp is surrounded by dentin, which is itself
coated on the crown by enamel and on the root by
cementum. Although the dental manifestations of XLH
have been well-reviewed, the responsible molecular
mechanisms are poorly understood [205]. Proposed
mechanisms are illustrated in Fig. 8.
Normal development of dental tissues
During normal dental development, collagenous preden-
tin is deposited by odontoblasts and matures into dentin
through two phases. The first phase involves formation
of calcium hydroxyapatite crystals as globules (or
Fig. 7 FGF23 and cranial abnormalities. Over-expression of FGF23 leads to up-regulation of FGFR2/3 signalling. Cross-binding of FGF23 with
FGFR2/3 at cranial sutures, impaired endochondral ossification of the skull, and osteomalacia-induced malformation of the base plate can all lead
to craniosynostosis
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calcospherules) in the predentin collagen fibres. The sec-
ond phase involves deposition of new areas of mineral-
isation that are layered onto the original crystals,
expanding them almost to the point of fusion.
Enamel formation (amelogenesis) commences after the
first layer of dentin has been deposited and continues in
repeated stages of secretion and maturation. The devel-
opment of enamel and dentin is thereafter mutually in-
duced, while deposition of cementum by cementoblasts
occurs later in tooth development.
Dentin defects
Although some incompletely-crystallised interglobular
dentin usually remains in the spaces between fully-
formed hydroxyapatite crystals, excess interglobular
dentin is a marker of certain dental abnormalities.
Severe under-mineralisation of circumpulpal dentin is
a hallmark of untreated children with XLH, whose teeth
contain large interglobular spaces, enlarged pulp cham-
bers, and prominent pulp horns that extend to the
dentino-enamel junction [207, 208]. The porous nature
of dentin in children with XLH makes their teeth prone
to bacterial invasion, abscesses, and necrosis [208],
which often occur “spontaneously” in the absence of
previous damage [112].
The presence of FGF23 mRNA in ameloblasts and
odontoblasts, along with observations of significant re-
ductions in mineral density, dental volume, and repara-
tive dentin area in Fgf23-TG mice indicates that FGF23
may be directly involved in dentinogenesis and mineral-
isation [209], as do observations of excess interglobular
dentin in Hyp and Fgf23-TG model mice from an early
age [209, 210].
Contrasting the high frequency of dental abscesses in
Hyp mice [211] with their relative absence in Phex- and
Fgf23-normal hypophosphatemic mouse models [212] or
in HHRH patients [213, 214] indicates that a phosphate-
independent mechanism is likely to contribute to forma-
tion of dental abscesses in XLH.
Furthermore, spontaneous dental abscesses have not
been reported as clinical features of TIO and iron-in-
duced osteomalacia, which are FGF23-high diseases of
hypophosphatemia that develop later in life. This may
indicate that hereditary hypophosphatemia and/or other
effects of FGF23 affects formation of dentin and enamel
structures during early dental development. Accordingly,
treatment with calcitriol and phosphate supplementa-
tion during the early time window of dental develop-
ment correlates with improved dental health later in
life [208, 215, 216].
Enamel defects
Enamel defects observed in XLH patients include micro-
clefts and irregular surface structure, through which bac-
teria could invade the tooth and form abscesses [217].
Evidence from rodent models indicates that enamel
phenotypes in XLH may be phosphate-independent and
mediated by calcitriol via osteocalcin [218–220].
Fig. 8 FGF23 and dental abnormalities. A schematic representation of molecular pathways that have been proposed to contribute to dental
manifestations of XLH
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However, reports of dental osteocalcin levels vary be-
tween Hyp and Fgf23-TG mouse models of XLH, which
have been reported to respectively up- and
down-regulate osteocalcin compared to wild type mice
[209]. If these results are accurate, there may be an
FGF23- and calcitriol-independent role of PHEX in me-
diating osteocalcin deposition.
Cementum defects
Loss of dental attachment is common in XLH, and can
result from defects in cementum, periodontal ligament
and/or alveolar bone [216].
Studies of Hyp and FGF23-/- mice have identified a
role for FGF23 in the development and maintenance of
the dentoalveolar complex [112, 221], and cementum
has been observed to be thinner in Hyp mice than in
wild type controls, with discontinuous mineralisation
and a globular appearance [210].
A variety of molecular mechanisms have been pro-
posed to contribute to cementum defects in XLH,
including sensitivity to local levels of phosphate [222]
and to altered regulation of TNAP [223]. Bone-targeted
TNAP has also rescued defects in cementum and alveo-
lar bone in patients with hypophosphatasia [205].
Calcitriol has also been reported to affect murine
cementogenesis in a DMP1- and FGF23-mediated man-
ner [224]. A role for FGF23 in regulation of cementum
is also indicated by the levels of bone sialoprotein (BSP)
(decreased) and DMP1 (elevated) in the cementum of
Fgf23−/− mice [225]. Furthermore, in human studies it
has been shown that early childhood initiation and
long-term persistence of conventional XLH therapy into
adulthood improves the periodontal deformities typical
of XLH, likely as a result of cementum and dentin defect
correction [216].
Despite the differences between tooth and bone develop-
ment, mineralisation of both tissues involves similar mo-
lecular processes and is often affected by similar molecular
mechanisms [205]. However, the effects of blocking FGF23
on dental development – of particular interest for treat-
ment of patients with XLH – have not been reported at this
stage [130, 131, 204].
Hearing loss
Patients with XLH have been observed to experience
hearing loss affecting low and high frequencies, which
can be associated with tinnitus and vertigo, and has been
compared to symptoms of endolymphatic hydrops
(ELH) [226–228].
Molecular mechanisms that have been reported to con-
tribute to hearing loss in XLH are depicted in Fig. 9, yet
the aetiology of endocrinological and metabolic hearing
loss is complex [229, 230], and the literature can be even
more difficult to interpret than for other manifestations.
As such, more work is needed to fully elucidate the
molecular links between FGF23, XLH and hearing
loss.
Hearing Loss and XLH
Reports of hearing loss in XLH patients are variable de-
pending on the age and selection criteria of the cohort
and range from 16% of subjects with hypophosphatemic
bone disease experiencing sensorineural hearing loss
[231], to 76% of subjects with X-linked hypophosphate-
mic osteomalacia experiencing hearing loss as detected
by pure tone audiometry [226]. In the latter study,
subjective hearing loss was reported by 48% of subjects.
Other studies have assessed conductive hearing loss
[226], sensorineural hearing loss [231], cochlear dysfunc-
tion [232] and electrical activity in the auditory centres
of the brain [230] with widely varying results. A more
standardised approach for assessing hearing loss is
clearly required for future studies.
A low prevalence of hearing loss has been reported in
many studies of XLH patients, and the cause of hearing
loss is often confounded by age, other genetic or envir-
onmental factors. Hearing loss in XLH patients and in
general has been observed to occur in certain families
[232], or in older patients who had experienced exces-
sive noise exposure [231]. The prevalence of hearing loss
has also been observed to vary between mouse models
of XLH with different Phex mutations, genetic back-
grounds or sex [77, 233]. These confounding factors
make it difficult to identify mechanisms that contribute
to hearing loss in XLH.
Hearing loss was first associated with specific Phex muta-
tions when Hyp mice (in which ear-related phenotypes had
not been observed) were compared to Gy mice (who were
commonly deaf) [70]. Potential contributions of PHEX and
FGF23 to hearing loss were confounded because both mu-
tations extended beyond the Phex coding region (Table 2),
and Gy mutations affected the nearby SmS gene, which has
been associated with hearing loss [234]. The role of FGF23
in XLH-related hearing loss should instead be studied using
animal models with Phex-specific mutations like Hyp-Duk,
Hyp-2J, and Ska1 mice.
Of the Phex-specific models, male Hyp-Duk mice
commonly displayed hearing loss, but Hyp-2J mice did
not [77]. Furthermore, the prevalence of hearing loss in
Hyp-Duk mutants decreased when the mice were
cross-bred onto different strains [233]. These confound-
ing effects of specific mutation and genetic background
on XLH-related hearing loss would be further com-
pounded when studying genetically diverse patients with
XLH that have various PHEX mutations. Nevertheless,
these findings have led the BALB/cUrd strain of
Hyp-Duk mice being used as a model for studying the
natural history of ELH [230, 233, 235].
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Endolymphatic hydrops
ELH has been associated with damage to the organ of
Corti and spiral ganglion neurons (SGNs) and is the
most well-studied mechanism of hearing loss in XLH
[226, 236]. The severity of ELH has also correlated with
the severity of hearing loss in Hyp-Duk mice [237].
ELH is caused by an inappropriate volume or compos-
ition of endolymph within the inner ear, and hearing loss
followed by neuronal loss and then hair cell loss is com-
monly observed in models of ELH [238, 239]. In the
Hyp-Duk model, ELH developed by P21 (21 days after
birth), SGN in the organ of Corti were lost by around
P90, and morphologically abnormal hair cells arose
much later (>P300) [239]. SGN loss in ELH progresses
from the apical to the basal cochlear turn and is at least
partially caused by apoptosis [77, 233, 239]. It is unclear
whether the relationship between ELH and SGN is
causative or correlative, although it has been suggested
that cell stress caused by elevated pressure associated
with hydrops may contribute to the observed apoptosis
[239]. The cause of ELH in XLH is also unclear [240].
With regards to the volume of endolymph, hearing
loss in the Hyp-Duk model of XLH does not consistently
correlate with increased endolymph space [77, 233], with
morphological abnormalities of the surrounding
temporal bone [77, 233], or with obstruction of the en-
dolymphatic duct [233]. Disruption of periductal chan-
nels embedded in the temporal bone is therefore a
candidate for contributing to ELH [230, 241], but has
not yet been studied in XLH.
Furthermore, although conventional therapy has been
observed to improve the bony structure surrounding the
ear and prevent osteoid deposition, the treatment did
not prevent ELH or hearing loss [230]. Unfortunately, in
this study mice were under-dosed with phosphate and
other symptoms were also unaffected, so a follow up
study would be required to test these findings [230].
The chemical composition of endolymph in XLH
could be altered by varied aural expression of ion chan-
nels [240] or through metabolic interactions with the
surrounding phosphate-deprived bone [230]. A
disrupted chemical composition could also be linked to
aural precipitates that have been observed in various
animal models of XLH [77, 242]. Characterising the
endolymphatic fluid and any precipitate in XLH patients
would shed light on this matter.
Inflammation and hearing loss
The reported formation of perilymphatic precipitate and
of inappropriate bone formation in the membranous
Fig. 9 Mechanisms of hearing loss in XLH. A schematic illustration of the structure of the ear is overlaid with the molecular pathways that may
connect FGF23 to hearing loss in XLH
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labyrinth (a potential mechanistic parallel to nephrocalci-
nosis or enthesopathy in XLH) [243] may also contribute
to inflammation (otitis media and serous labyrinthitis),
which has in turn been linked to ELH [244] and to hearing
loss in XLH [62, 233, 243].
However, these results have all come from animal
studies, and otitis media has not been observed in XLH
patients [62]. To determine if these animal models are
suitable, XLH patients that experience hearing loss
should therefore be assessed for inflammation and have
their DNA sequenced for mutations that resemble Gy or
Hyp-Duk.
Other XLH manifestations
Patients with XLH rarely report symptoms related to a
weakened immune system, however FGF23 has been
connected to the innate immune system in CKD, impair-
ing neutrophil recruitment [44, 245] and the antimicro-
bial molecule LL37 synthesis in peripheral blood
mononuclear cell monocytes [246]. FGF23 has also been
connected to increased deaths by infectious diseases
[247]. As these sequelae have not been connected to
XLH, they are beyond the scope of this article, and we
refer to a recent review of the subject [246].
Conclusions
Since FGF23 was identified as the causative agent of ADHR
and TIO, it has been shown to play a key role in the path-
ology of XLH and most other inherited hypophosphatemic
diseases. This review has described literature exploring the
mechanisms by which excess FGF23 contributes to the
clinical manifestations and morbidity of XLH.
There has been considerable advancement in the under-
standing of XLH pathogenesis over the last two decades.
Indeed, most manifestations of XLH are now known to be
caused by FGF23-induced hypophosphatemia resulting
from downregulation of sodium-phosphate transporters in
the renal distal tubule, and repression of serum calcitriol.
In addition, local repression of calcitriol and TNAP may
also inhibit mineralisation via FGF23-mediated upregula-
tion and loss of PHEX-mediated degradation of OPN and
pASARM, alongside accumulation of PPi.
These roles of FGF23 in XLH pathology have been
further demonstrated by anti-FGF23 antibody treatment,
which can normalise phosphate and vitamin D metabol-
ism and improve rachitic changes in XLH patients [133]
and Hyp mice [130–132].
To further elucidate the role of FGF23 in manifestations
of XLH, it is important to clearly define and compare the
causes and manifestations of other diseases of hypopho-
sphatemia and their representative animal models. Studies
assessing individual manifestations of XLH are often
under-powered and generate vastly different estimates of
frequency, intensity, and correlation with specific
genotypes.
Larger patient registries and multicentre studies that
include greater numbers of XLH patients are needed to
further clarify the prevalence, phenotypic spectrum,
genotype-phenotype correlation, and response to treat-
ment of patients with XLH.
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